Evidence associated with screening for high fracture risk
Please note this is not an exhaustive list, with papers listed in chronological order.
Zoulakis M, Axelsson KF, Litsne H, et al. Real-world effectiveness of osteoporosis screening in older Swedish women (SUPERB). Bone. 2024 Oct;187:117204.
Petersen T, Abrahamsen B, Høiberg M, et al. Ten-year follow-up of fracture risk in a systematic population-based screening program: the risk-stratified osteoporosis strategy evaluation (ROSE) randomised trial. EClinicalMedicine. 2024;71:102584.
Whitty C. Chief Medical Officer’s annual report 2023: Health in an ageing society.; 2023.
Chotiyarnwong P, McCloskey E, Harvey N, et al. Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group. Arch Osteoporos. 2022;17(1):87.
All Party Parliamentary Group (APPG) for Osteoporosis and Bone Health. APPG on osteoporosis and bone health inquiry report: fracture prevention and osteoporosis in primary care.; 2022.
UK National Screening Committee (NSC). Updated definition of targeted screening will help clarify remit of expanded UK NSC. Published 2022.
UK National Screening Committee (NSC). UK NSC guidance criteria for a targeted screening programme. Published 2022.
Söreskog E, Borgström F, Shepstone L, et al. Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. Osteoporosis International. 2020;31(8):1499-1506.
Merlijn T, Swart KMA, van der Horst HE, Netelenbos JC, Elders PJM. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporosis International. 2020;31(2):251-257.
Parsons C, Harvey N, Shepstone L, et al. Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporosis International. 2020;31(1):67-75.
UK National Screening Committee (NSC). UK NSC Osteoporosis Screening Recommendation and 2019 Review.
Merlijn T, Swart K, van Schoor N, et al. The effect of a screening and treatment program for the prevention of fractures in older women: a randomized pragmatic trial. Journal of Bone and Mineral Research. 2019;34(11):1993-2000.
Rubin KH, Rothmann MJ, Holmberg T, et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporosis International. 2018;29(3):567-578.
McCloskey E, Johansson H, Harvey N, et al. Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures—a post hoc analysis of the SCOOP study. Journal of Bone and Mineral Research. 2018;33(6):1020-1026.
Turner D, Khioe R, Shepstone L, et al. The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: economic evaluation of the SCOOP study. Journal of Bone and Mineral Research. 2018;33(5):845-851.
Shepstone L, Lenaghan E, Cooper C, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. The Lancet. 2018;391(10122):741-747.
Shepstone L, Fordham R, Lenaghan E, et al. A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporosis International. 2012;23(10):2507-2515.
Emmett CL, Redmond NM, Peters TJ, et al. Acceptability of screening to prevent osteoporotic fractures: a qualitative study with older women. Fam Pract. 2012;29(2):235-242.
